Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study: A Randomised, Multicenter Open-Label Phase III Study of Neoadjuvant Lapatinib, Trastuzumab and Their Combination Plus Paclitaxel in Women With HER2/ErbB2 Positive Primary Breast Cancer

Trial Profile

Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study: A Randomised, Multicenter Open-Label Phase III Study of Neoadjuvant Lapatinib, Trastuzumab and Their Combination Plus Paclitaxel in Women With HER2/ErbB2 Positive Primary Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Jul 2018

At a glance

  • Drugs Lapatinib (Primary) ; Trastuzumab (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Paclitaxel
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms Neo-ALTTO; NeoALTTO
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 05 Jun 2018 Results assessing outcome of pregnancies occurring during or following trastuzumab and/or lapatinib in NeoALTTO and ALTTO trials (n=92) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results (n=245) of a genomic analysis presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 Results assessing association between adaptive immune signature and clinical outcome by using data from this and other study presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top